EyePoint Pharmaceuticals (EYPT) is a Potential Acquisition Target, But Well-Positioned to Execute on its Own - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating and $31.00 price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
